pDONR223-DAPK3 Citations (3)
Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal
Articles Citing pDONR223-DAPK3
| Articles |
|---|
| DAPK3 suppresses acini morphogenesis and is required for mouse development. Kocher BA, White LS, Piwnica-Worms D. Mol Cancer Res. 2015 Feb;13(2):358-67. doi: 10.1158/1541-7786.MCR-14-0333. Epub 2014 Oct 10. PubMed |
An open library of human kinase domain constructs for automated bacterial expression.
Albanese SK, Parton DL, Isik M, Rodriguez-Laureano L, Hanson SM, Behr JM, Gradia S, Jeans C, Levinson NM, Seeliger MA, Chodera JD.
Biochemistry. 2018 Jul 13. doi: 10.1021/acs.biochem.7b01081.
PubMed
Associated Plasmids |
| The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING-IFN-beta pathway. Takahashi M, Lio CJ, Campeau A, Steger M, Ay F, Mann M, Gonzalez DJ, Jain M, Sharma S. Nat Immunol. 2021 Apr;22(4):485-496. doi: 10.1038/s41590-021-00896-3. Epub 2021 Mar 25. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.